News

Blincyto was recently approved by the FDA to treat CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

In part 4 of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA discusses how the organization is looking to expand into different global regions and continue leading awareness for the clinical research industry.

The investigational prophylactic monoclonal antibody met its primary endpoints, reducing infections up to day-150.

Results from an induction trial and maintenance trial show Skyrizi (risankizumab) improved endoscopic and histological secondary outcomes characterized by endoscopic improvement, remission, and histological, endoscopic, and mucosal improvements in patients with moderately to severely active ulcerative colitis.

In part 3 of this video interview, Carie Pierce, SVP, global head of growth & business development, DIA highlights the most relevant themes related to clinical trials that were present at DIA including DE&I and patient recruitment.

Carie Pierce, SVP, global head of growth & business development, DIA touches on the various themes of the sessions which were held at the 2024 Global Annual Meeting including regulatory, technology, and harmonization.

Dovato regimen met its primary endpoint at 48 weeks for the treatment of HIV-1 in people who are virologically suppressed.

Antibody-mediated rejection is the primary cause of kidney allograft failure following kidney transplantation.

Pierce shares her greatest takeaways from this year's meeting in San Diego, CA.

Study finds a potential risk of adverse events associated with long-term use of oral corticosteroids in patients with exacerbations of atopic dermatitis.

Study met its primary endpoint with statistically significant superior efficacy over 12 weeks of treatment compared to placebo.

Paxlovid was the first oral drug approved by the FDA to treat Covid-19 in adults who do not require supplemental oxygen and who have an increased risk of progression to severe disease.

Wearables have great potential to continue advancing research in Rett syndrome as well as other rare disease areas.

The androgen receptor inhibitor significantly increased radiological progression-free survival in combination with androgen deprivation therapy compared to placebo.

Two-year data from duo of Phase III studies show potential for Susvimo as an alternative to eye injections to treat diabetic macular edema and diabetic retinopathy.

Altuviiio is a first-in-class, high-sustained factor VIII replacement therapy, indicated for routine prophylaxis and on-demand treatment to control bleeding episodes in adults and children with hemophilia.

Mixed methods study gathered responses from study investigators to identify barriers, solutions, and opportunities associated with continuing critical care randomized trials during the pandemic.

Newly released research report from Information Services Group suggests firms are moving away from traditional, centralized trials in favor of remote technologies.

Study shows patients 80 years and older with atrial fibrillation treated with a lower dose of edoxaban experienced fewer major gastrointestinal bleeding events for each additional ischemic stroke.

deLaubenfels addresses key challenges seen by sponsors and highlights the value cough monitoring can provide.

Topline results from the 52-week open-label trial show the treatment was well tolerated with a safety profile consistent with standard-of-care.

Phase III RAISE trial shows superiorty of reteplase over alteplase in improving patients’ functional outcomes without increasing incidence of symptomatic intracranial hemorrhage and death from ischemic stroke within 4.5 hours after symptom onset.

The potential treatment for chemotherapy-induced peripheral neuropathy will be evaluated in a single ascending dose study.

In a Phase I-II trial, CM313 was found to inhibit antibody-dependent cell-mediated cytotoxicity on platelets while achieving long-term efficacy in patients with immune thrombocytopenia.

Del Smith, PhD, co-founder & CEO of Acclinate highlights challenges sponsors may face in light of FDA releasing its Diversity Action Plan guidance.

NF2-related schwannomatosis is a relentlessly progressive tumor predisposition syndrome with no FDA-approved treatments.

Emerging data from Phase I first-in-human, dose-escalation study showed promising survival and progression-free survival rates.

Smith shares his initial thoughts on the guidance and what its impact will be on the industry moving forward.